000277751 001__ 277751
000277751 005__ 20240229155022.0
000277751 0247_ $$2doi$$a10.5603/RPOR.a2023.0022
000277751 0247_ $$2pmid$$apmid:37456699
000277751 0247_ $$2pmc$$apmc:PMC10348326
000277751 0247_ $$2ISSN$$a1507-1367
000277751 0247_ $$2ISSN$$a1428-2267
000277751 0247_ $$2ISSN$$a2083-4640
000277751 037__ $$aDKFZ-2023-01468
000277751 041__ $$aEnglish
000277751 082__ $$a610
000277751 1001_ $$aWolf, Robert J$$b0
000277751 245__ $$aIntensity-modulated radiotherapy for the management of primary and recurrent chordomas: a retrospective long-term follow-up study.
000277751 260__ $$aPoznań$$bGreat Poland Cancer Centre$$c2023
000277751 3367_ $$2DRIVER$$aarticle
000277751 3367_ $$2DataCite$$aOutput Types/Journal article
000277751 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692022765_20940
000277751 3367_ $$2BibTeX$$aARTICLE
000277751 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277751 3367_ $$00$$2EndNote$$aJournal Article
000277751 500__ $$a#LA:E050#
000277751 520__ $$aChordomas have a high risk of recurrence. Radiotherapy (RT) is required as adjuvant therapy after resection. Sufficient radiation doses for local control (LC) can be achieved using either particle therapy, if this technology is available and feasible, or intensity-modulated radiotherapy.57 patients (age, 11.8-81.6 years) with chordomas of the skull base, spine and pelvis who received photon radiotherapy between 1995 and 2017 were enrolled in the study. Patients were treated at the time of initial diagnosis (68.4%) or during recurrence (31.6%). 44 patients received adjuvant radiotherapy and 13 received definitive radiotherapy. The median total dose to the physical target volume was 70 Gy equivalent dose in 2 Gy fractions (EQD2) (range: 54.7-82.5) in 22-36 fractions.LC was 76.4%, 58.4%, 46.7% and 39.9% and overall survival (OS) was 98.3%, 89%, 76.9% and 47.9% after 1, 3, 5 and 10 years, respectively, with a median follow-up period of 6.5 years (range, 0.5-24.3 years). Age, dose and treatment concept (post-operative or definitive) were significant prognostic factors for OS. Primary treatment, macroscopic tumour at RT and size of the irradiated volume were statistically significant prognostic factors for LC.Photon treatment is a safe and effective treatment for chordomas if no particle therapy is available. The best results can be achieved against primary tumours if the application of curative doses is possible due to organs at risk in direct proximity. We recommend high-dose radiotherapy, regardless of the resection status, as part of the initial treatment of chordoma, using the high conformal radiation technique if particle therapy is not feasible.
000277751 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000277751 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277751 650_7 $$2Other$$achordoma
000277751 650_7 $$2Other$$along-term follow-up
000277751 650_7 $$2Other$$aphoton
000277751 650_7 $$2Other$$aradiotherapy
000277751 7001_ $$aWinkler, Volker$$b1
000277751 7001_ $$aMattke, Matthias$$b2
000277751 7001_ $$aUhl, Matthias$$b3
000277751 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b4$$eLast author$$udkfz
000277751 773__ $$0PERI:(DE-600)2494467-1$$a10.5603/RPOR.a2023.0022$$gVol. 28, no. 2, p. 207 - 216$$n2$$p207 - 216$$tReports of practical oncology and radiotherapy$$v28$$x1507-1367$$y2023
000277751 909CO $$ooai:inrepo02.dkfz.de:277751$$pVDB
000277751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000277751 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000277751 9141_ $$y2023
000277751 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2022-01-18T09:46:01Z
000277751 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bREP PRACT ONCOL RADI : 2022$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-12-29T11:33:47Z
000277751 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-12-29T11:33:47Z
000277751 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-12-29T11:33:47Z
000277751 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000277751 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000277751 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000277751 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000277751 980__ $$ajournal
000277751 980__ $$aVDB
000277751 980__ $$aI:(DE-He78)E050-20160331
000277751 980__ $$aUNRESTRICTED